Clifford Swan Investment Counsel LLC Has $21.75 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Clifford Swan Investment Counsel LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 210,276 shares of the company’s stock after selling 1,791 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Novo Nordisk A/S were worth $21,753,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Pacific Center for Financial Services increased its stake in Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. Bell Investment Advisors Inc raised its holdings in shares of Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after buying an additional 127 shares in the last quarter. CNB Bank bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $26,000. Citizens National Bank Trust Department boosted its stake in Novo Nordisk A/S by 100.0% in the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares in the last quarter. Finally, Tyler Stone Wealth Management grew its position in Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after acquiring an additional 146 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on NVO shares. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Trading Down 0.8 %

NVO traded down $0.97 during trading on Friday, reaching $123.05. 5,932,926 shares of the company’s stock were exchanged, compared to its average volume of 3,905,318. The firm has a fifty day moving average price of $127.20 and a two-hundred day moving average price of $113.10. The stock has a market capitalization of $552.19 billion, a PE ratio of 42.43, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.